Redefining pain management after cardiac surgery to improve intensive care and hospital length of stay: a randomised pilot trial.

Not Applicable

Completed

• Conditions: Coronary Artery Disease; Cardiovascular - Coronary heart disease; Anaesthesiology - Pain management; Physical Medicine / Rehabilitation - Physiotherapy

• Registration Number: ACTRN12612001243808
• Lead Sponsor: Cardiac Surgery, Intensive Care Unit and Physiotherapy Department at Liverpool Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-11-26
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 75

Inclusion Criteria

The participant must meet ALL the criteria listed below for entry:
1. Participant speaks English
2. Participant can read English
3. Participant must be 18 years or older, and may be of either sex and of any race.
4. Participant is scheduled or will be scheduled for Coronary Artery Graft Surgery (CAGS) with at least one left internal mammary artery

Exclusion Criteria

The participant will be excluded from entry if ANY of the criteria listed below are met:
1. Hypersensitivity to amide-type local anesthetics, verapamil, ciprofloxacin, and norfloxacin.
2. Women of childbearing potential
3. Current severe congestive heart failure (NYHA heart failure class more than and equal to 3).
4. Cardiogenic shock (systolic blood pressure more or equal to 90mm/Hg with or without inotropes, or on inotropes) before randomisation.
5. Left ventricular ejection fraction (LVEF) < 30% (or more than mild dysfunction on echocardiogram).
6. Acute/chronic renal impairment (creatinine level of more or equal to 160umol/L)
7. Significant liver disease (bilirubin level of > 2x the upper limit of normal), inadequate haematologic function (haemoglobin level of < 90g/L, white blood cell count of < 2.5 x 10(9)/L, neutrophil count of less than 1.0 x 10(9)/L, and platelet count of <100 x 10(9)/L).
8. Severe vasculopathy with significant thrombo-occlusive thoracoabdominal aortic disease
9. Logistic EuroSCORE risk of mortality more than and equal to 6%.
10. Use of fluvoxamine (Luvox) at the time of consent.

Study & Design

• Study Type: Interventional
• Study Design: Not specified